Aberrant methylation of the CDKN2A/p16INK4A gene promoter region in preinvasive bronchial lesions: A prospective study in high-risk patients without invasive cancer

International Journal of Cancer

Volumn 100, Issue 2, 2002, Pages 189-193

  Lamy, Aude ^a   Sesboüé, Richard ^a   Bourguignon, Jeannette ^a   Dautréaux, Brigitte ^a   Métayer, Josette ^b   Frébourg, Thierry ^a   Thiberville, Luc ^b  

^a INSERM   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Bronchial biopsies; CDKN2A p16INK4a; NSCLC; Promoter methylation

Indexed keywords

CARCINOGEN; PROTEIN CDKN2A; PROTEIN P16; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRONCHUS BIOPSY; BRONCHUS CANCER; BRONCHUS MUCOSA; CANCER GRADING; CARCINOGENESIS; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA METHYLATION; ENDOSCOPY; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; MALIGNANT TRANSFORMATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR;

ASBESTOS; BIOPSY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; EPITHELIAL CELLS; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; METAPLASIA; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 0037054936     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10474     Document Type: Article

References (42)

1. The multistep nature of cancer development
2. Bronchial and pulmonary carcinogenesis at focal sites in dogs and hamsters
3. Changes in bronchial epithelium in relation to cigarette smoking and cancer of the lung
4. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus
5. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance
6. Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions
7. Expression of p16 and lack of pRB in primary small cell lung cancer
8. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines
9. Rb and p16INK4a expression in resected non-small cell lung tumors
10. Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma
11. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
12. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers
13. Alterations of CDKN2 (p16) in non-small cell lung cancer
14. Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK41 (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas
15. Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers
16. Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas
17. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers
18. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine
19. Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers
20. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers
21. Aberrant promoter methylation of multiple genes in non-small cell lung cancers
22. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer
23. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines
24. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage
25. Frequent aberrant methylation of p16INK4a in primary rat lung tumors
26. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis
27. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis
28. Predicting lung cancer by detecting aberrant promoter methylation in sputum
29. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy
30. Expansion of bronchial epithelial cell populations by in vitro culture of explants from dysplastic and histologically normal sites
31. Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation
32. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
33. Demethylation by 5-aza-2′-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells
34. Histological typing of lung and pleural tumors, with contributions by pathologists from 14 countries
35. Hypermethylation of the caveolin-1 gene promoter in prostate cancer
36. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies
37. Re: Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas
38. Hypermethylation at 9q32-33 tumor suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer
39. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53
40. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers
41. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers